Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add filters








Language
Year range
1.
Braz. j. med. biol. res ; 39(7): 945-955, July 2006. ilus
Article in English | LILACS | ID: lil-431562

ABSTRACT

Findings by our group have shown that the dorsolateral telencephalon of Gymnotus carapo sends efferents to the mesencephalic torus semicircularis dorsalis (TSd) and that presumably this connection is involved in the changes in electric organ discharge (EOD) and in skeletomotor responses observed following microinjections of GABA A antagonist bicuculline into this telencephalic region. Other studies have implicated the TSd or its mammalian homologue, the inferior colliculus, in defensive responses. In the present study, we explore the possible involvement of the TSd and of the GABA-ergic system in the modulation of the electric and skeletomotor displays. For this purpose, different doses of bicuculline (0.98, 0.49, 0.245, and 0.015 mM) and muscimol (15.35 mM) were microinjected (0.1 æL) in the TSd of the awake G. carapo. Microinjection of bicuculline induced dose-dependent interruptions of EOD and increased skeletomotor activity resembling defense displays. The effects of the two highest doses showed maximum values at 5 min (4.3 ± 2.7 and 3.8 ± 2.0 Hz, P < 0.05) and persisted until 10 min (11 ± 5.7 and 8.7 ± 5.2 Hz, P < 0.05). Microinjections of muscimol were ineffective. During the interruptions of EOD, the novelty response (increased frequency in response to sensory novelties) induced by an electric stimulus delivered by a pair of electrodes placed in the water of the experimental cuvette was reduced or abolished. These data suggest that the GABA-ergic mechanisms of the TSd inhibit the neural substrate of the defense reaction at this midbrain level.


Subject(s)
Animals , Behavior, Animal/physiology , Bicuculline/pharmacology , Gymnotiformes/physiology , Mesencephalon/physiology , Muscimol/pharmacology , Behavior, Animal/drug effects , Bicuculline/administration & dosage , Defense Mechanisms , Drug Interactions/physiology , Electric Stimulation , Electric Organ/drug effects , Electric Organ/physiology , GABA Agonists/pharmacology , GABA Antagonists/pharmacology , Microinjections , Mesencephalon/drug effects , Movement/drug effects , Movement/physiology , Muscimol/administration & dosage , Neural Pathways/drug effects , Neural Pathways/physiology
2.
Braz. J. Psychiatry (São Paulo, 1999, Impr.) ; 27(3): 243-248, set. 2005. tab
Article in English | LILACS | ID: lil-413117

ABSTRACT

Recentes evidências sugerem que as moléculas críticas nas cascatas de sinalizacão neurotrófica são alvos de longo prazo dos antidepressivos monoaminérgicos disponíveis atualmente. Na medida em que transtornos graves e crônicos são caracterizados por deficiências na resiliência neuronal, estratégias farmacológicas que sejam úteis para uma funcão neuroprotetora talvez possam alterar a fisiopatologia e modificar a progressão da doenca. Vários enfoques promissores envolvem a modulacão do sistema neurotransmissor do glutamato, via bloqueio ou potencializacão do receptor pós-sináptico e inibicão da liberacão vesicular pré-sináptica. Foi realizada uma revisão focada da literatura científica existente, com a discussão de três compostos ou classes de drogas que estão atualmente sob investigacão clínica: a ketamina, o riluzol e os potencializadores de receptores de AMPA. DISCUSSAO: Estudos recentes com pacientes com transtornos de humor sugerem que a ketamina, um antagonista do receptor NMDA, poderia ter demonstrado propriedades antidepressivas rápidas. O riluzol demonstrou reverter deficiências mediadas pelo glutamato na plasticidade neuronal e estimular a síntese de fatores neurotróficos derivados do cérebro. Ensaios abertos com depressão resistente ao tratamento produziram resultados promissores. Da mesma forma, os potencializadores de receptores de AMPA impactam favoravelmente os fatores neurotróficos, assim como melhoram a cognicão. CONCLUSÕES: Enfoques farmacológicos que modulam os componentes do sistema de glutamato oferecem novos alvos para transtornos de humor recorrentes e graves. São necessários estudos controlados.


Subject(s)
Animals , Humans , Antidepressive Agents/therapeutic use , Excitatory Amino Acid Antagonists/therapeutic use , Ketamine/therapeutic use , Mood Disorders/drug therapy , Receptors, AMPA/therapeutic use , Riluzole/therapeutic use , Antidepressive Agents/pharmacology , Excitatory Amino Acid Antagonists/pharmacology , Ketamine/pharmacology , Neural Pathways/drug effects , Receptors, AMPA/antagonists & inhibitors , Riluzole/pharmacology , Synaptic Transmission/drug effects
3.
Indian J Physiol Pharmacol ; 2004 Apr; 48(2): 137-49
Article in English | IMSEAR | ID: sea-108680

ABSTRACT

The medial preoptic area (mPOA) is one of the many areas in the brain that control sleep. Apart from sleep, the mPOA is important for the regulation of body temperature, and other important body functions aimed at energy homeostasis. In sleep regulation, the major function of this area is to maintain sleep. Though the mPOA controls sleep and body temperature through independent neuronal circuits, it is essential for organising the sleep architecture, as per the thermoregulatory requirement. The functional integrity of the mPOA may be essential for the regulation of energy homeostasis, in response to alterations in the ambient temperature, heat producing physical activity and sleep-wakefulness. Thus, the mPOA forms part of the brain that integrates regulations aimed at preservation of self. The mPOA is important for maintaining the "set point" for not only body temperature, but it is also important for maintaining the "set point" for several physiological parameters including sleep-wakefulness.


Subject(s)
Animals , Humans , Neural Pathways/drug effects , Norepinephrine/pharmacology , Preoptic Area/drug effects , Sleep/drug effects
SELECTION OF CITATIONS
SEARCH DETAIL